Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) 5-Year EBITDA Growth Rate : 2.10% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Beijing Tong Ren Tang Chinese Medicine Co 5-Year EBITDA Growth Rate?

Beijing Tong Ren Tang Chinese Medicine Co's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.40.

During the past 12 months, Beijing Tong Ren Tang Chinese Medicine Co's average EBITDA Per Share Growth Rate was -14.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 0.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 2.10% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 10.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Beijing Tong Ren Tang Chinese Medicine Co was 56.80% per year. The lowest was 0.30% per year. And the median was 11.50% per year.

Competitive Comparison of Beijing Tong Ren Tang Chinese Medicine Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Tong Ren Tang Chinese Medicine Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Tong Ren Tang Chinese Medicine Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Beijing Tong Ren Tang Chinese Medicine Co's 5-Year EBITDA Growth Rate falls into.

Beijing Tong Ren Tang Chinese Medicine Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Beijing Tong Ren Tang Chinese Medicine Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Beijing Tong Ren Tang Chinese Medicine Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing Tong Ren Tang Chinese Medicine Co Ltd (HKSE:03613) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

TQR:Germany

Address

Convention Plaza, 1 Harbour Road, Room 1405-1409, Office Tower, Wanchai, Hong Kong, HKG

Website

https://cm.tongrentang.com

Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products, Mainland China (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Mainland China and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd, and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.

Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Headlines

No Headlines